Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.46 |
| ▸ | PARP1 | P09874 | 2/20 | 0.45 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4502102 | 0.87 | KDM4E (0.55) | KDM4EPKMPRMT5PARP1TGFBR1 | |
| SCHEMBL4488299 | 0.81 | USP1 (0.45) | PARP1 | |
| SCHEMBL4495617 | 0.81 | PARP1 (0.56) | KDM4EPKMPRMT5PARP1TGFBR1 | |
| SCHEMBL4503780 | 0.80 | PARP1 (0.56) | KDM4EPKMPRMT5PARP1TGFBR1 | |
| SCHEMBL4496187 | 0.80 | PARP1 (0.49) | KDM4EPKMPRMT5PARP1BCDIN3D | |
| SCHEMBL8354967 | 0.77 | BACE1 (0.53) | PRMT5TGFBR1 | |
| SCHEMBL12846151 | 0.77 | KDM4E (0.54) | KDM4EPKMPRMT5IDO1TDO2 | |
| SCHEMBL4495515 | 0.76 | PARP1 (0.55) | KDM4EPKMPRMT5PARP1 | |
| SCHEMBL4495524 | 0.76 | PARP1 (0.51) | KDM4EPKMPRMT5PARP1TGFBR1 | |
| SCHEMBL4502894 | 0.76 | ACHE (0.60) | GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1502916-A1 | PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | KDM4E 3395/4885PKM 3885/4885PRMT5 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.